In EGFR-mutated NSCLC cells, the MAPK pathway enhances PD-L1 expression by modulating drug resistance mechanisms like c-MET amplification and EGFR-T790M mutation, resulting in resistance to EGFR-TKIs (177, 178). Here, EGFR is linked to non-small cell lung carcinoma.